Luise Fischer

Leipzig, SN, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

We included a total of 87 patients who received CAR T-cell therapy: 54 with none/mild chronic kidney disease (CKD) and 33 with moderate/severe CKD.

We included a total of 87 patients who received CAR T-cell therapy: 54 with none/mild chronic kidney disease (CKD) and 33 with moderate/severe CKD.

Journal: Transplantation and cellular therapy

Published: February 10, 2026

MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel.

MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel.

Journal: Leukemia

Published: October 14, 2025

Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myeloma.

Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myeloma.

Journal: HemaSphere

Published: September 11, 2025

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma.

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma.

Journal: Cancer cell

Published: May 05, 2025

Prognostic Implications of Splenomegaly in BCMA-Directed CAR T-Cell Therapy for Relapsed Myeloma.

Prognostic Implications of Splenomegaly in BCMA-Directed CAR T-Cell Therapy for Relapsed Myeloma.

Journal: Transplantation and cellular therapy

Published: March 28, 2025

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma.

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma.

Journal: HemaSphere

Published: February 13, 2025

Virtual twins for personalised CAR T-cell therapy in myeloma.

Virtual twins for personalised CAR T-cell therapy in myeloma.

Journal: The Lancet. Haematology

Published: October 28, 2024

Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies.

Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies.

Journal: NPJ digital medicine

Published: August 30, 2024

Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma.

Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma.

Journal: Blood cancer discovery

Published: May 09, 2024

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 15, 2024

Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma.

Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 18, 2024

Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma.

Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma.

Journal: Leukemia

Published: September 28, 2023

Showing 1-12 of 27

Last Updated: 09/26/2026